Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) is projected to release its earnings data before the market opens on Thursday, March 20th. Analysts expect Xenetic Biosciences to post earnings of ($0.20) per share and revenue of $0.18 million for the quarter.
Xenetic Biosciences Stock Up 4.9 %
Xenetic Biosciences stock opened at $3.67 on Tuesday. The stock has a 50-day simple moving average of $4.03 and a 200 day simple moving average of $4.01. Xenetic Biosciences has a 12-month low of $2.78 and a 12-month high of $5.20. The stock has a market capitalization of $5.66 million, a price-to-earnings ratio of -1.38 and a beta of 2.17.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Xenetic Biosciences in a report on Thursday, December 5th.
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.
Read More
- Five stocks we like better than Xenetic Biosciences
- Upcoming IPO Stock Lockup Period, Explained
- Can TikTok Stock Picks Really Make You Rich?
- How to invest in marijuana stocks in 7 steps
- The “Quality” Rotation: Back to Basics Investing
- Investing in Travel Stocks Benefits
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
